Opposite alterations of 5HT₂A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile

Rebeca Diez-Alarcia¹, Carolina Muguruza¹, Guadalupe Rivero¹, Aintzane García-Bea², Vanessa Gómez-Vallejo³, Luis F. Callado³, Jordi Llop⁴, Abraham Martín⁵ and J. Javier Meana¹,²,³

Abstract
The status of serotonin 5HT₂A receptors (5HT₂ARs) in schizophrenia has been controversial. In vivo positron emission tomography neuroimaging and in vitro post-mortem binding studies have reported conflicting results about 5HT₂AR density. Radiotracers bind different receptor conformations depending on their agonist, antagonist or inverse agonist properties. This study investigates 5HT₂AR density in the post-mortem prefrontal cortex from subjects with schizophrenia and controls using three radiotracers with a different pharmacological profile. The specific binding parameters of the inverse agonist [¹⁸F]altanserin, the agonist [³H]lysergic acid diethylamide (LSD) and the antagonist [³H]MDL100907 to brain cortex membranes from 20 subjects with schizophrenia and 20 individually matched controls were evaluated under similar methodological conditions. Ten schizophrenia subjects were antipsychotic-free at death. Saturation curve analyses were performed by non-linear regression to obtain a maximal density of binding sites (Bₘₐₓ) and the affinity of the respective radiotracers (Kᵋ). In schizophrenia subjects, 5-HT₂AR density was decreased when quantified by [¹⁸F]altanserin binding, whereas increased when evaluated by [³H]LSD binding. However, [³H]MDL100907 binding was unaltered. A slight loss of affinity (higher Kᵋ) was observed exclusively in [³H]LSD binding. The findings were more evident in antipsychotic-free subjects than in antipsychotic-treated subjects. In conclusion, a higher proportion of the 5-HT₂A-acting functional conformation, which is rather identified by agonist radiotracers, was observed in schizophrenia patients. A consequent reduction of the inactive 5-HT₂AR conformation, which is preferentially identified by inverse agonist radiotracers, was also obtained. Antagonist radiotracers do not distinguish between molecular conformations of the receptor, and accordingly, the absence of changes was shown. These results are compatible with the proposed increased functional activity of brain cortical 5-HT₂ARs in schizophrenia.

Introduction
A role for serotonin (5-HT) in the pathophysiology and therapeutics of schizophrenia is supported by converging observations. First, similarities between psychotic states in psychiatric disorders and the effects of lysergic acid diethylamide (LSD) and other 5-HT receptor-mediated psychedelic drugs (e.g., mescaline and psilocybin) have been described. Second, cortical serotonin 5HT₂A receptors (5-HT₂ARs) seem to be the critical target to induce these psychosis-like responses, and second-generation antipsychotics such as clozapine, risperidone and olanzapine, among others, display potent antagonism properties on 5-HT₂ARs. Furthermore, since 5-HT plays a key role in emotional processing, it has been proposed that dysregulation of 5-HT neurotransmission could underlie the negative symptoms of schizophrenia. The 5-HT receptor brain density is typically assessed in vivo using positron emission tomography (PET) and in vitro...
using post-mortem tissue homogenates and sections (for a review, see Supplementary Table S1). Evidence shows a lower density of 5-HT2A receptors in the frontal cortex of antipsychotic-naïve schizophrenic patients when evaluated with the very selective (200- to 500-fold higher affinity for 5-HT2A vs. dopamine D2 receptors (D2Rs)) radiotracer [18F]altanserin. In contrast, inconclusive results were obtained with other radiotracers such as [18F]N-methyl spiperone and [18F]N,N-dimethyl 3-(2-furyl)propylpiperazine ([F]FDL100907) which have 10- to 25-fold 5-HT2A selectivity vs. dopamine D2Rs. Since D2Rs are clearly involved in schizophrenia pathophysiology and treatment, the use of these radiotracers with substantial D2R affinity is considered a source of bias for 5-HT2A detection. On the other hand, important differences among studies have also been obtained from in vitro post-mortem studies in the brain of subjects with schizophrenia. Thus, while some studies described up-regulation of 5HT2A receptors, others pointed towards the absence of alterations or even a down-regulation in the number of binding sites. These apparent discrepancies among post-mortem studies have been considered in the context of different demographic and clinical parameters, the existence of diverse pharmacological treatments and the variety of methodological approaches. Moreover, as drug-free populations are difficult to obtain for post-mortem studies, the existence of long-term antipsychotic treatment has been considered the main explanatory factor for differences between in vivo neuroimaging studies in drug-naïve patients and in vitro findings in post-mortem brain. However, less attention has been paid to the pharmacological properties, such as agonist, antagonist or inverse agonist, of the respective drugs used as radiotracer tools to identify 5HT2A receptors. The most common 5HT2A drugs used to generate radioligands for in vivo PET studies ([18F]altanserin and [11C]M100907) are considered antagonists, and the efforts towards the development of agonist radiotracers have reported limited success. In marked contrast, post-mortem studies of 5HT2A quantitation in schizophrenia have been performed with the agonist [3H]LSD and the partial agonist [3H]ketanserin radiotracers (Supplementary Table S1). Although unattended, the pharmacological properties, such as agonist, antagonist or inverse agonist, are determinants for the receptor conformation identified by the radiotracer and, subsequently, for the estimated binding density.

G-protein-coupled receptors (GPCRs) and, among them, 5HT2A Rs display different molecular conformations that are interchangeable and stay in equilibrium. Thus, the receptor conformation that couples to G proteins is considered to be functionally active and represents the high-affinity state of the receptor, which is preferentially identified by agonist radioligands. Conversely, inverse agonist radioligands show preference to bind the low-affinity state, i.e., the inactive receptor conformation, which is uncoupled from G proteins. Finally, antagonist radioligands bind with similar affinity to both receptor conformations (Fig. 1). Therefore, the binding of agonist radioligands to the G-protein-coupled conformation should serve as a more accurate measure of 5HT2A functions and dysfunctions than antagonist binding.

In vitro studies have revealed increased functional coupling of 5HT2A Rs to G proteins in the brain cortex of subjects with schizophrenia without alterations in total values of receptor density. This finding suggests that an imbalance of 5HT2A Rs towards the high-affinity receptor conformation might be present in schizophrenia, leading to overactive G-protein-dependent signalling. Under this 5HT2A overactivity, enhanced agonist radioligand binding should be expected. Conversely, a decreased binding of inverse agonist radioligands to the uncoupled conformation might indicate a decrease of the low-affinity receptor state and prove the existence of an imbalance between coupled and uncoupled 5HT2A Rs conformations in schizophrenia, with receptor equilibrium displaced towards the active conformational state (Fig. 2).

Although [18F]altanserin and [11C]MDL100907 were initially developed as selective antagonist radiotracers to quantify 5HT2A Rs in PET studies, altanserin has recently been demonstrated to show inverse agonist properties.
In fact, [18F]altanserin binding is decreased in the brain of subjects with schizophrenia, leading to opposite hypothesis. Howver, the 5HT2AR receptor binding of agonist, antagonist and inverse agonist radioligands should label lower binding sites in schizophrenia than in controls. Antagonist radioligands would not discriminate between schizophrenia and control subjects.

The aim of the present study was to investigate the 5HT2AR density in post-mortem prefrontal cortex of subjects with schizophrenia, using three different radiotracers with different intrinsic activity properties (agonist, antagonist and inverse agonist) on this receptor. [3H]LSD, [3H]MDL100907 and [18F]altanserin were selected as representative radiotracers with well-established pharmacological profiles. LSD is a hallucinogenic drug with 5HT2AR partial agonist properties, and its [3H]-labelled form identifies this receptor under blocking conditions for other 5-HT receptors. MDL100907 is a very selective 5-HT2AR antagonist, whose [18F]- and [11C]-labelled forms have been used for PET studies. Altanserin is a highly selective 5HT2AR inverse agonist, commonly considered as antagonist PET radiotracer when labelled with [18F]. The three radiotracers were evaluated on saturation binding experiments in brain cortex membrane homogenates of the same subjects and under similar experimental conditions. We sought to test the hypothesis that different alterations of 5HT2AR density are obtained in schizophrenia depending on the intrinsic activity properties of each radiotracer. The results would shed light on the unclarified status of brain 5HT2ARs in schizophrenia.

**Subjects, materials and methods**

**Post-mortem human brain samples**

Brain samples were obtained at autopsies performed in the Basque Institute of Legal Medicine, Bilbao, Spain, in compliance with policies of research and ethical boards for post-mortem brain studies. Deaths were subjected to retrospective searching for previous medical diagnosis and treatment using the examiner’s information and records from hospitals and mental health centres. A total number of 20 brains from subjects with ante-mortem diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV, DSM-IV-TR) were matched to 20 brains from control subjects in a paired design. Control subjects were chosen among the collected brains on the basis of the absence of neuropsychiatric disorders or drug abuse, and an appropriate sex, storage time and post-mortem interval (elapsed time between death and tissue dissection/freezing) to match each schizophrenia subject. Toxicological screening of blood samples of all subjects was performed to determine the presence at death of antipsychotics, other drugs and ethanol. According to the absence or presence of antipsychotic drugs in this toxicological screening, schizophrenia population was divided into two groups, a group of antipsychotic-free (n = 10) and a group of antipsychotic-treated (n = 10) subjects. Schizophrenia and control groups were similar for sex ratio, age, storage time and post-mortem interval values (Supplementary Table S2). Seventeen out of the 20 subjects in the schizophrenia group committed suicide. Matched control subjects mainly died by accidental causes. Therefore, the mechanism of death indicates that almost all were violent or sudden. Specimens of the dorsolateral prefrontal cortex (Brodmann’s area 9) were dissected at autopsy following standard procedures and immediately stored at -80°C until assayed. A complete description of the whole population of subjects with schizophrenia and their individually matched controls can be found in Supplementary Table S2. Some of the schizophrenia cases and controls have been previously used to evaluate the [3H]LSD, [3H]MDL100907 and [18F]altanserin.
ketanserin binding density\textsuperscript{13,24} and G-protein activation mediated by 5-HT\textsubscript{2A}Rs\textsuperscript{20,29} (see Supplementary Table S2 for details). The prefrontal cortex was selected as the region of interest based on the morphological alterations associated to schizophrenia\textsuperscript{30} and the large expression of 5-HT\textsubscript{2A}Rs in the area\textsuperscript{5}.

**Materials and drugs**

MDL100907 (volinanserin) and altanserin were purchased from Sigma-Aldrich. \textsuperscript{[3]}H]LSD (86.3 Ci/mmol at delivery time) was obtained from PerkinElmer Life and Analytical Sciences, Inc., and \textsuperscript{[3]}H]MDL100907 (80 Ci/mmol at delivery time) was obtained from ARC Radiochemicals. All other chemicals were obtained from standard sources.

**Synthesis of \textsuperscript{[18]}F-altanserin**

\textsuperscript{[18]}F-altanserin was produced in a TRACERlab FXFN synthesis module (GE Healthcare) by radiofluorination of nitro-altanserin (ABX, Radeberg, Germany) as previously published\textsuperscript{31}. Specific activity at initial incubation time (see below) was in the range 300–700 GBq/μmol. The average radiochemical yield was 11 ± 4% (end of synthesis). Radiochemical purity was >97% in all cases.

**Brain membranes preparation**

Brain cortex samples were processed to obtain membrane-enriched homogenates as previously described\textsuperscript{13}.

\textsuperscript{[18]}F-altanserin, \textsuperscript{[3]}H]LSD and \textsuperscript{[3]}H]MDL100907 binding assays

Complete saturation binding assays were performed with \textsuperscript{[18]}F-altanserin (0.03–4 nM, eight concentrations), \textsuperscript{[3]}H]LSD (0.03–10 nM, ten concentrations) and \textsuperscript{[3]}H]MDL100907 (0.007–4 nM, ten concentrations) in order to determine the density (\(B_{\text{max}}\)) and the affinity (\(K_d\)) of 5-HT\textsubscript{2A}Rs. Incubation was carried out in tubes (\textsuperscript{[18]}F-altanserin) or 96-well plates (\textsuperscript{[3]}H]LSD and \textsuperscript{[3]}H]MDL100907) and started with the addition of the brain membrane preparation. Reactions were incubated for 40 min at 37°C for \textsuperscript{[18]}F-altanserin binding assays and 90 min at 37°C for \textsuperscript{[3]}H]LSD and \textsuperscript{[3]}H]MDL100907 binding assays. The presence of MDL100907 (1 μM) or altanserin (10 μM) was used to determine the non-specific binding of \textsuperscript{[18]}F-altanserin and \textsuperscript{[3]}H]LSD, and of \textsuperscript{[3]}H]MDL100907, respectively. After incubation, free radioligand was separated from bound radioligand by rapid filtration under vacuum through GF/C glass fibre filters pre-soaked with 0.5% polyethylenimine and counted for radioactivity gamma counting (\textsuperscript{[18]}F-altanserin; 2470 WIZARD2 Automatic Gamma Counter, PerkinElmer) or by liquid scintillation (\textsuperscript{[3]}H]LSD and \textsuperscript{[3]}H]MDL100907; MicroBeta TriLux Counter, PerkinElmer). Results were corrected for each radiotracer decay. Pairs of cases and controls were always processed at the same time and all samples were run in duplicate.

**Data and statistical analyses**

Data obtained from saturation binding experiments of each subject were analysed by non-linear regression using the GraphPad Prism\textsuperscript{™} software. The apparent equilibrium dissociation constant (\(K_d\)) and the maximum density of specific binding sites (\(B_{\text{max}}\)) were obtained. \(K_d\) values were normalized to log transformation before parametric analyses. All data were subjected to a Grubbs’s test in order to detect and reject possible outlier values among experimental groups. Pearson’s correlation \(r\) coefficient was calculated to test for a possible association between independent covariables (age, post-mortem interval and storage time) and receptor density. When correlation was significant, analysis of covariance was performed controlling for the independent covariable. One-way analysis of variance followed by Bonferroni’s post-hoc test was used to compare results between radioligands. Results are expressed as mean±standard deviation (SD) of individual values.

Statistical comparisons between groups were conducted by non-linear curve-fitting coanalysis of all individual binding experiments. The selection between a single-curve model (absence of differences between groups) and a two-curve model (statistical differences between groups) was made by the extrusam-of-squares \(F\) test using GraphPad Prism\textsuperscript{™}. When statistical differences between curves were obtained, further individual contrasts were performed to detect whether differences were attributable to changes in \(B_{\text{max}}\) and/or \(K_d\) values between groups\textsuperscript{32,33}. The analysis that permitted one or more of the parameters to be shared without a significant increase in the residual variance was taken as the best fit. In this non-linear analysis, results (\(B_{\text{max}}\) and \(K_d\)) are expressed as the best estimation parameter ± SD. These values obtained from simultaneous non-linear regression analyses were not used for parametric statistical calculations.

In all analyses, the level of statistical two-tailed significance was chosen as \(p = 0.05\).

**Results**

**Specific binding sites for \textsuperscript{[18]}F-altanserin, \textsuperscript{[3]}H]LSD and \textsuperscript{[3]}H]MDL100907**

The individual non-linear analysis of each radioligand binding fitted to a saturation curve displaying a single specific binding site of high affinity, compatible with selective detection of 5-HT\textsubscript{2A}Rs. The receptor density (\(B_{\text{max}}\)) in the overall population was similar when identified by \textsuperscript{[18]}F-altanserin or \textsuperscript{[3]}H]MDL100907 binding, while it was significantly higher when estimated by \textsuperscript{[3]}H]LSD binding (192 ± 82% over \textsuperscript{[18]}F-altanserin, \(p < 0.01\); 210 ± 89% over \textsuperscript{[3]}H]MDL100907, \(p < 0.0001\)). The binding
affinities, expressed by $K_d$ values, were always in the nanomolar range ($K_d = 0.36 \pm 0.19$ nM for $[^{18}F]_\text{altanserin}$; $K_d = 1.26 \pm 0.86$ nM for $[^{18}F]_\text{LSD}$; $K_d = 0.47 \pm 0.37$ nM for $[^{3}H]_\text{MDL100907}$) without significant differences between radioligands.

Positive correlations between densities obtained with $[^{18}F]_\text{altanserin}$ and $[^{18}F]_\text{LSD}$ ($r = 0.332$, $p < 0.05$), and between $[^{3}H]_\text{MDL100907}$ and $[^{18}F]_\text{LSD}$ ($r = 0.894$, $p < 0.0001$) were found. In contrast, no significant correlation was found between densities obtained with $[^{18}F]_\text{altanserin}$ and $[^{3}H]_\text{LSD}$, suggesting that these radioligands could identify different binding populations.

### Effects of demographic parameters and post-mortem conditions

The density of $[^{18}F]_\text{altanserin}$ binding sites displayed a negative correlation with the age at death ($r = -0.341$; $p < 0.05$). According to this linear decay, the average decrease per decade for $5\text{-HT}_{2A}$Rs was $35 \pm 15$ fmol/mg.

In the case of $[^{3}H]_\text{MDL100907}$ binding, there was also a decrease of density with age ($30 \pm 17$ fmol/mg per decade) that did not reach significant correlation ($r = -0.283$; $p = 0.08$). No correlation between age at death and density of $[^{3}H]_\text{LSD}$ binding sites was obtained.

$[^{18}F]_\text{altanserin}$, $[^{3}H]_\text{LSD}$ and $[^{3}H]_\text{MDL100907}$ binding properties were not significantly affected neither by post-mortem interval nor by storage time at $-80^\circ\text{C}$.

### Comparison between schizophrenia and control groups

The co-analysis of saturation curves obtained with $[^{18}F]_\text{altanserin}$ showed a statistically significant reduction of the density of the binding sites in the schizophrenia group compared to matched controls. No differences in affinity were detected between schizophrenia and control groups (Table 1). When the presence of antipsychotic drugs was considered, the co-analysis demonstrated a significant reduction of $[^{18}F]_\text{altanserin}$ binding sites in antipsychotic-free subjects with schizophrenia ($B_{\max} = 329 \pm 24$ fmol/mg) vs. matched controls ($B_{\max} = 410 \pm 25$ fmol/mg) ($p < 0.05$) (Fig. 3A). In contrast, subjects with schizophrenia and presence of antipsychotic treatment displayed density values ($B_{\max} = 376 \pm 18$ fmol/mg) closer to the respective matched control group ($B_{\max} = 411 \pm 23$ fmol/mg) (Fig. 3A). No changes were observed in the affinity parameters ($K_d = 0.30 \pm 0.07$ nM in antipsychotic-free schizophrenia group vs. $K_d = 0.34 \pm 0.07$ nM in matched controls; $K_d = 0.33 \pm 0.05$ nM in antipsychotic-treated schizophrenia group vs. $K_d = 0.29 \pm 0.06$ nM in matched controls). As expected, these findings were confirmed by analysis of covariance controlling $B_{\max}$ value for age.

The co-analysis of saturation curves obtained with $[^{3}H]_\text{LSD}$ demonstrated a significant increase of binding sites in subjects with schizophrenia compared to matched controls. The co-analysis also demonstrated higher $K_d$ values of this radioligand in the schizophrenia group than in controls (Table 1). When the presence of antipsychotic drugs in blood was considered, the enhanced receptor density was maintained in antipsychotic-free schizophrenia subjects ($B_{\max} = 791 \pm 69$ fmol/mg) when compared with matched controls ($B_{\max} = 646 \pm 34$ fmol/mg) ($p < 0.05$) (Fig. 3B). Conversely, antipsychotic-treated schizophrenia subjects displayed receptor density values ($B_{\max} = 735 \pm 63$ fmol/mg) that did not differ from those in respective control group ($B_{\max} = 635 \pm 30$ fmol/mg) (Fig. 3B). In the case of $K_d$ values, the increase was significant for both antipsychotic-free ($K_d = 1.45 \pm 0.45$ nM) and antipsychotic-treated ($K_d = 1.52 \pm 0.44$ nM) schizophrenia subjects compared with respective controls ($K_d = 0.69 \pm 0.15$ nM and $K_d = 0.77 \pm 0.15$ nM) ($p < 0.05$). Re-evaluation with age as covariate maintained similar results. In order to test whether the residual presence of antipsychotic drugs could contribute to the increased $K_d$ of $[^{3}H]_\text{LSD}$ binding, a correlation between published $K_d$ values for $5\text{-HT}_{2A}$AR values of drugs detected in the post-mortem toxicological screening and individual $K_d$ values was performed. A significant

### Table 1 Radioligand binding parameters in the prefrontal cortex of subjects with schizophrenia and matched controls.

| Radioligand | Schizophrenia | Control | $F$ (d.f., d.f.) | $p$ Value |
|-------------|---------------|---------|-----------------|-----------|
| $[^{18}F]_\text{altanserin}$ | $B_{\max}$ | $K_d$ | $n$ | $B_{\max}$ | $K_d$ | $n$ | $F$ (d.f., d.f.) | $p$ Value |
| Mean ± SD | Mean ± SD | | | Mean ± SD | Mean ± SD | | |
| $352 \pm 15$ | $0.32 \pm 0.05$ | 20 | 410 ± 17 | $0.32 \pm 0.05$ | 20 | $F(1,288) = 6.361$ | 0.0122 |
| $765 \pm 47$ | $1.5 \pm 0.32$ | 20 | $640 \pm 23$ | $0.73 \pm 0.11$ | 20 | $F(1,311) = 8.282$ | 0.0043 |
| $324 \pm 23$ | $0.29 \pm 0.07$ | 20 | $335 \pm 16$ | $0.28 \pm 0.04$ | 20 | $F(1,294) = 0.354$ | 0.7023 |

For each radioligand, the two sets of data (schizophrenia and control) were first analysed separately. The overall value for the sum of squares and the degrees of freedom (d.f.) was the sum of the individual values of each fit. Next, the two sets of data were pooled and analysed simultaneously constraining them to share one or two common parameters ($B_{\max}, K_d$). The pooled fit yielded values for the sum of squares and degrees of freedom. The analysis that permitted one or two parameters to be shared without a significant increase in the residual variance was taken as the best fit. $[^{18}F]_\text{altanserin}$ and $[^{3}H]_\text{LSD}$ binding curves were considered different between schizophrenia and control. The subsequent analysis demonstrated that statistical differences were adscribed to different $B_{\max}$ but not to $K_d$ values. The $F$, d.f. and $p$ values displayed correspond to this condition. For $[^{3}H]_\text{MDL100907}$, estimations obtained under equivalent analysis are shown.
correlation \( (r = 0.68, \ p = 0.04) \) was obtained in antipsychotic-treated subjects.

The co-analysis of curves obtained with \([3H]\)MDL100907 showed no differences of binding sites between subjects with schizophrenia and matched controls. The affinities were also similar (Table 1). No differences were detected neither in antipsychotic-free schizophrenia subjects \((B_{\text{max}} = 324 \pm 37 \text{ fmol/mg}; \ K_d = 0.34 \pm 0.13 \text{ nM})\) with respective controls \((B_{\text{max}} = 328 \pm 23 \text{ fmol/mg}; \ K_d = 0.32 \pm 0.07 \text{ nM})\) nor in antipsychotic-treated subjects \((B_{\text{max}} = 330 \pm 28 \text{ fmol/mg}; \ K_d = 0.26 \pm 0.07 \text{ nM})\) vs. matched controls \((B_{\text{max}} = 344 \pm 22 \text{ fmol/mg}; \ K_d = 0.25 \pm 0.05 \text{ nM})\) (Fig. 3C). Age at death did not influence the results in the analysis of covariance.

**Discussion**

The present study demonstrates in post-mortem human frontal cortex that alterations of 5-HT2ARs observed in schizophrenia are dependent on the pharmacological properties of the radiotracer used to identify this receptor. Thus, binding assays with an agonist \([3H]\)LSD, an antagonist \([3H]\)MDL100907 and an inverse agonist \([18F]\)altanserin radiotracer conducted in similar incubation conditions from identical samples lead to different results. The present study provides evidence that the agonist radioligand binding to 5-HT2ARs is increased in schizophrenia, whereas inverse agonist radioligand binding is reduced, and the antagonist radioligand binding remains unaltered. This differential pattern is remarkable in antipsychotic-free subjects, whereas the presence of these drugs in blood tends to reverse the 5-HT2AR density alterations to control values. Until recently, an equivalent PET study was not feasible, mainly due to the lack of suitable agonist radiotracers for selective 5-HT2AR identification\(^36\). However, the recent development of \([11C]\)Cimbi-36\(^15,18\), a non-selective 5-HT\(_{2A/B/C}\)R agonist\(^37\), could help to confirm through head-to-head in vivo comparisons between antagonist and inverse agonist radiotracers the findings here reported in the post-mortem tissue. Nevertheless, the technical and ethical feasibility of in vivo identification of 5-HT\(_{2A}\)Rs by three different PET radiotracers in the same patient and short time frame is limited. Therefore, in vitro post-mortem studies could help to overcome these drawbacks in the study of neurotransmitter receptor molecular alterations. However, other potentially confounding factors, especially the existence of previous treatment with antipsychotic drugs, add limitations to the conclusions of post mortem studies. In fact, the number of antipsychotic-free subjects included in this type of studies is very limited\(^38\) (Supplementary Table S1).

The increased density of 5-HT\(_{2A}\)Rs identified by the agonist radiotracer \([3H]\)LSD confirms the proposed higher functional sensitivity of this receptor in schizophrenia.
Previous studies with the partial agonist radioligand $[^{3}H]$ ketanserin have reported similar findings in antipsychotic-free subjects. Enogenous and exogenous agonists bind preferentially to the high-affinity state of the receptor, which represents the active functional conformation coupled to cell signalling pathways (Fig. 1). Recently, the assessment of 5-HT$_{2A}$R coupling to G proteins in post-mortem frontal cortex has demonstrated an enhanced sensitivity of inhibitory G$_{i3}$ proteins in response to the agonist (±)DOI (2,5-dimethoxy-4-iodoamphetamine) in schizophrenia. In concordance, the prolactin response to the 5-HT-releasing drug d-fenfluramine, which is considered a functional in vivo test dependent on 5-HT$_{2A/C}$Rs activation, is enhanced in drug-free schizophrenia subjects. Therefore, evidence points towards a functional hyperactivity of 5-HT$_{2A}$Rs in schizophrenia. This issue has resulted in controversy since PET studies with $[^{18}F]$altanserin have suggested decreased binding potential in antipsychotic-naive schizophrenia patients. The present study illustrates how the reduction of $[^{18}F]$altanserin binding (−20%) is compatible with enhanced binding (+22%) of agonist radiotracers as $[^{3}H]$ketanserin and $[^{3}H]$LSD. The compound altanserin has been classically regarded as the selective 5-HT$_{2A}$R antagonist. However, in the brain cortex, this drug shows inverse agonist properties, which means preferential labelling to the receptor conformation uncoupled from G proteins. In this way, the pharmacological profile of $[^{18}F]$altanserin explains the reduced 5-HT$_{2A}$R density reported in schizophrenia as a reduction of the uncoupled conformation of this receptor. G-protein-coupled (higher affinity for agonists than for inverse agonists) and G-protein-uncoupled (higher affinity for inverse agonists than for agonists) receptor conformations are interchangeable molecular states of GPCRs. In brains of subjects with schizophrenia, the imbalance between 5-HT$_{2A}$R conformations in favour of the G-protein-coupled state would be expressed as increased density of the agonist $[^{3}H]$LSD binding and reduced density of the inverse agonist $[^{3}H]$altanserin binding, as observed in the present study (Fig. 2). Moreover, this hypothesis should be supported by the concurrent absence of changes in the 5-HT$_{2A}$R density delineated by selective antagonist radiotracers. Neutral antagonist drugs do not distinguish among molecular conformations of the receptor and, thereby, are not suitable tools to detect the existence of imbalance between 5-HT$_{2A}$R conformational states in schizophrenia. The absence of differences for the antagonist $[^{3}H]$MDL100907 binding between schizophrenia and control groups obtained in the present study agrees with this argument and supports the existence of a functional 5-HT$_{2A}$R imbalance in the pathophysiology of the disorder. More recent post-mortem studies have added further weight to this hypothesis by showing that messenger RNA expression and total protein immunodetection of 5-HT$_{2A}$Rs are unaltered in subjects with schizophrenia free of antipsychotic treatment.

One apparent inconsistency of the present study is the different receptor binding density obtained between radiotracers. $[^{3}H]$LSD approximately identified a two-fold higher number of binding sites than $[^{18}F]$altanserin and $[^{3}H]$MDL100907. It is widely accepted that 5-HT$_{2A}$Rs are assembled into homodimeric and heterodimeric structures. Receptor oligomers coexist with monomeric forms (Fig. 4). Dimeric receptor complex crosstalk to each other promoting differential modulation of the ligand access to the respective binding pockets. In fact, the binding of partial agonist and antagonists, as ketanserin and MDL100907, to one of the two binding sites in the 5-HT$_{2A}$R homodimer introduces negative cooperativity effects on the propensity of a second molecule of the same drug to bind the dimer. In contrast, the hallucinogenic 5-HT$_{2A}$R agonist (±)DOB shows a similar affinity for the two binding sites of the dimer. Therefore, it is feasible to propose that $[^{3}H]$LSD is able to label the two binding sites of the homodimeric 5-HT$_{2A}$R, whereas $[^{3}H]$MDL100907, $[^{18}F]$altanserin and $[^{3}H]$ketanserin binding to one of the receptor pockets prevent the own radioligand binding to the second site (Fig. 4). This molecular mechanism would be reflected in a two-fold higher density when estimated by radiotracers bound to the full homodimer with respect to the density obtained by radiotracers bound only to one of the monomers that conform to the dimer. The results shown in the present study together with those in previous studies with the radiotracer $[^{3}H]$ketanserin agree with this hypothesis of a homodimeric 5-HT$_{2A}$R structure and function. Certainly, the assumption of the receptor oligomerization paradigm should affect future comparisons between radiotracer binding properties.

The observed decline of 5-HT$_{2A}$R density with ageing is a repeated finding in previous post-mortem and PET studies. This profound effect of ageing provides the rationale for experimental designs based on one-to-one individual matching of each schizophrenia case with respective control, as performed here, rather than the usual and less rigorous group-based matching.

The presence or absence at death of antipsychotic drugs in the blood of subjects with schizophrenia represents another relevant confounding factor in radioligand binding studies (Supplementary Table S1). In the present study, the absence of antipsychotic drugs in the toxicological analysis does not mean that these subjects termed as antipsychotic-free were antipsychotic-naive, but rather that they were untreated in the nearest ante-mortem period. The more $[^{18}F]$altanserin binding and the less $[^{3}H]$LSD binding densities in antipsychotic-treated respect to antipsychotic-free schizophrenia subjects suggest that antipsychotic treatment would counterbalance the 5-HT$_{2A}$Rs alterations observed in schizophrenia.
Long-term treatment with second-generation antipsychotics modulates 5-HT2A R expression in animals\textsuperscript{14,24} and could modify binding parameters due to residual presence of antipsychotics acting as 5-HT2A R antagonists\textsuperscript{20}. However, the possibility that observed alterations of 5-HT2A R density ($B_{\text{max}}$) in schizophrenia represent a consequence of the current or past long-term antipsychotic treatment is improbable. First, the changes of density are more evident in recent antipsychotic-free than in antipsychotic-treated subjects. Second, the differential up- or down-regulation of 5-HT2A Rs associated with recent antipsychotic treatment in function of the different radiotracers makes unlikely a residual competitive effect between the antipsychotic and the radioligand to bind the receptor pocket. In contrast to density ($B_{\text{max}}$), the apparent affinity ($K_d$ value) was sensitive to the residual presence of antipsychotic drugs, although this effect was only observed for $[^3H]$LSD binding assays. The finding reasserts the use of agonist radiotracers to better detect the 5-HT2A R occupation by psychedelic drugs\textsuperscript{46}. Receptor exploration in drug-free conditions is more feasible by PET imaging than by retrospective post-mortem binding studies. Indeed, most of the post-mortem studies evaluating 5-HT2A Rs in schizophrenia have been performed in the brain of subjects under antipsychotic treatment, which probably led to inconclusive results (Supplementary Table S1). Besides this, when schizophrenia subjects were differentiated between those under antipsychotic treatment and those antipsychotic-free, the post-mortem radioligand studies demonstrated up-regulation of brain 5-HT2A Rs identified by agonist/partial agonist radiotracers\textsuperscript{13,20,23,24}. Therefore, in order to discard eventual bias in post-mortem studies, independent and well-matched groups of antipsychotic-free and antipsychotic-treated subjects should be selected and independently analysed.

Another potential confounding factor to consider in the present study is the fact that schizophrenia subjects died mostly from violent suicide mechanisms. Suicide has been proposed as a condition that could influence the evaluation of 5-HT2A Rs\textsuperscript{47}. However, there are several studies in the frontal cortex of suicide victims with a variety of psychiatric disorders supporting that suicide unlikely represents a major confounder in 5-HT2A R binding studies\textsuperscript{1,13,48,49}.

In conclusion, the study and interpretation of 5-HT2A R dysfunctions in schizophrenia requires a deep knowledge of the pharmacological properties of the candidate radiotracers. The distinction of 5-HT2A R radiotracers between agonist, antagonist and inverse agonist may shed light on the, up to now, contradictory results. According to the different pharmacological profile, the present results and most of the studies would demonstrate an upregulation of the active functional 5-HT2A R conformation in the brain of subjects with schizophrenia.

The present results support the hypothesis that 5-HT2A R molecular conformation and/or the receptor interaction with other synaptic proteins might be altered in schizophrenia. Moreover, as previously described, the antipsychotic treatment seems also to modify the
functional state of 5-HT$_{2A}$Rs, trying to revert the alterations found in antipsychotic-free schizophrenia subjects. Therefore, the development and in vivo use of agonist radiotracers in antipsychotic-naïve patients should be encouraged to validate the 5-HT$_{2A}$R overactivity here proposed.

Acknowledgements
This study was supported by the Spanish State Research Agency, Ministry of Science and ERD Funds (SAF-2009-08460, SAF-2017-88126-R, RYC-2017-22412 and CTQ-2017-87637-R), and the Basque Government (SAOTEK S-PE13UN019 and IT-1211-19). Part of this work was conducted under the Maria de Maeztu Units of Excellence Programme (Grant MDM-2017-0720). C.M. and A.G.-B. were recipients of fellowships from the Marie Sklodowska-Curie Programme (European Union’s Horizon 2020, Grant 774867) and the Basque Government postdoctoral training Programme, respectively. We wish to thank staff members, and especially Dr. B. Morentin, of the Basque Institute of Legal Medicine, Bilbao, Spain, for their cooperation in the study.

Author details
1Department of Pharmacology, University of the Basque Country, Leioa, Bizkaia, Spain. 2Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Leioa, Bizkaia, Spain. 3Biocruces Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain. 4CIC BioMaGUNE, Basque Research and Technology Alliance (BRTA), Donostia/San Sebastian, Spain. 5Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain. 6Achucarro Basque Center for Neuroscience, Leioa, Bizkaia, Spain. 7IKERBASQUE Basque Foundation for Science, Bilbao, Spain.

Conflict of interest
The authors declare no biomedical financial interests or potential competing interests. The funding sources had no role in the design, collection, analysis and interpretation of data, writing of the report, or the decision to submit the article for publication.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
The online version contains supplementary material available at https://doi.org/10.1038/s41398-021-01430-7.

Received: 1 October 2020 Revised: 26 April 2021 Accepted: 5 May 2021

Published online: 20 May 2021

References
1. Selvaraj, S., Amon, D., Cappai, A. & Howes, O. Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci. Biobehav. Rev. 45, 233–245 (2014).
2. Geyer, M. A. & Vollm Biederer, F. X. Serotonin research: contributions to understanding psychoses. Trends Pharmacol. Sci. 29, 445–453 (2008).
3. Gonzalez-Maeso, J. & Sealfon, S. Psychopharmacology and schizophrenia. Trends Neurosci. 32, 225–232 (2009).
4. Paterson, L. M., Komum, B. R., Nutt, D. J., Pike, V. W. & Knudsen, G. M. 5-HT7 receptor ligands for human brain imaging with PET and SPECT. Med. Res. Rev. 33, 54–111 (2013).
5. Rasmussen, H. et al. Decreased frontal serotonin2A receptor binding in antipsychotic-naïve patients with first-episode schizophrenia. Arch. Gen. Psychiatry 67, 9–16 (2010).
6. Rasmussen, H. et al. Low frontal serotonin 2A receptor binding is a state marker for schizophrenia? Eur. Neuropsychopharmacol. 26, 1248–1250 (2016).
7. Entino, E. D. et al. Cortical and subcortical 5-HT$_{2A}$ receptor binding in neuroleptic-naïve first-episode schizophrenia patients. Neuropsychopharmacology 33, 2435–2441 (2008).
8. Trichard, C. et al. No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr. Res. 31, 13–17 (1998).
9. Ngal, T. T., Yatham, L. N., Ruth, T. J. & Liddle, P. F. Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: a PET study using $[^{18}$F]setoperone. Am. J. Psychiatry 157, 1016–1018 (2000).
10. Verhoef, N. P. et al. A voxel-by-voxel analysis of $[^{11}$C]setoperone PET data shows no substantial serotonin 5-HT2A receptor changes in schizophrenia. Psychiatry Res 99, 123–135 (2000).
11. Okubo, Y. et al. Serotonin 5-HT2 receptor in schizophrenic patients studied by positron emission tomography. Life Sci. 66, 2455–2464 (2000).
12. Dean, B. The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice. J. Neurochem. 85, 1–13 (2003).
13. Mugurusa, C. et al. Dysregulated 5-HT(2A) receptor binding in postmortem frontal cortex of schizophrenic subjects. Eur. Neuropsychopharmacol. 23, 652–684 (2013).
14. Dean, B. Crossland, N., Boer, S. & Scarf, E. Evidence for altered post-receptor modulation of the serotonin 2A receptor in schizophrenia. Schizophr. Res. 104, 185–197 (2008).
15. L’Estrade, E. T. et al. Classics in neuroimaging: the serotonergic 2A receptor system – from discovery to modern molecular imaging. ACS Chem. Neurosci. 9, 1226–1239 (2018).
16. Lopez-Gimenez, J. et al. Multiple conformations of native and recombinant human 5-hydroxytryptamine$_{2A}$ receptors are labeled by agonists and discriminated by antagonists. Mol. Pharmacol. 60, 690–699 (2001).
17. Battaglia, G., Shannon, M. & Teiter, M. Guanyl nucleotide and cation regulation of cortical 52 serotonin receptors. J. Neurochem. 43, 1213–1219 (1984).
18. Etrup, A. et al. Serotonin 2A receptor agonist binding in the human brain with $[^{11}$C]Cimbi-36. J. Cereb. Blood Flow Metab. 34, 1188–1196 (2014).
19. Colom, M., Vidal, B. & Zimmer, L. Is there a role for GPCR agonist radiotracers in PET neuroimaging? Front. Mol. Neurosci. 12, 255 (2019).
20. Garcia-Bea, A. et al. Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: selective biased agonism via G$_{85}$-proteins. Eur. Neuropsychopharmacol. 29, 1453–1463 (2019).
21. Diez-Alarcia, R. et al. Big data challenges targeting proteins in GPCR signaling pathways, combining PTM/cheRium models and $[^{11}$C]GTPyS binding assays. ACS Chem. Neurosci. 10, 4476–4491 (2019).
22. Hurlermann, R. et al. 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology 195, 579–590 (2008).
23. Whitaker, P. M., Crow, T. J. & Ferrier, I. N. Trisalted LSD binding in frontal cortex in schizophrenia. Arch. Gen. Psychiatry 38, 278–280 (1981).
24. Gonzalez-Maeso, J. et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452, 93–97 (2008).
25. Nichols, D. E. Psychopharmacol. Rev. 68, 264–355 (2016).
26. Kim, K. et al. Structure of a hallucinogen-activated Gq-coupled 5-HT$_{2A}$ serotonin receptor. Cell 182, 1574–1588 (2020).
27. Johnson, M. P., Siegel, B. W. & Carr, A. A. $[^{11}$C]MDL 100,907: a novel selective 5-HT2A receptor ligand. Naunyn Schmiedebergs Arch. Pharmacol. 354, 205–209 (1996).
28. Talbot, P. S. et al. Extended characterisation of the serotonin 2A (5-HT$_{2A}$) receptor-selective PET radiotracer $[^{11}$C]-MDL100907 in humans: quantitative analysis, test-retest reproducibility, and vulnerability to endogenous 5-HT tone. Neuroimage 59, 271–285 (2012).
29. Ogada, Y., Kinoshita, M., Meana, J. J., Callado, L. F. & García-Sevila, J. A. 5-HT$_{2A}$ receptor-mediated G$_{85}$-activation in psychiatric disorders: a postmortem study. J. World J. Biol. Psychiatry. https://doi.org/10.1080/15622975.20201839967 (2021).
30. Lewis, D. A. & González-Burgos, G. Neuropolycticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 33, 141–165 (2008).
31. Martin, A. et al. PET imaging of serotonergic neurotransmission with $[^{11}$C]DASB and $[^{18}$F]Faltanserin after focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 33, 1967–1975 (2013).
32. De Leen, A., Munson, P. J. & Rodbard, D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 235, E97–E102 (1978).
33. Motulsky, M. J. & Ransnas, L. A. Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J. 1, 365–374 (1987).
34. Lal, S., Nair, N. P. V., Ceccy, D. & Quinson, R. Levoempropanoprazine receptor binding profile in human brain - implications for treatment-resistant schizophrenia. Acta Psychiatr. Scand. 87, 380–383 (1993).
35. Psychoactive Drug Screening Program (PDSP) database. https://pdsp.unmc.edu/databases/kidb.php (2021).
36. Shalgunov, V. et al. Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: theoretical and practical considerations for positron tomography imaging. Med. Res. Rev. 39, 1014–1052 (2019).
37. Ettrup, A. et al. Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36: test–retest reproducibility and head-to-head comparison with the antagonist [18F]altanserin. Neuroimage 130, 167–174 (2016).
38. McCullumsmith, R. E., Hammond, J. H., Shan, D. & Meador-Woodruff, J. H. Postmortem brain: an underutilized substrate for studying severe mental illness. Neuropsychopharmacology 39, 65–87 (2014).
39. Jones, H., Curtis, V. A., Wright, P. & Lucey, J. V. Neuroendocrine evidence that clozapine’s serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms. Am. J. Psychiatry 155, 838–840 (1998).
40. Abel, K. M, O’Keane, V. & Murray, R. M. Enhancement of the prolactin response to D-fenfluramine in drug-naive schizophrenia patients. Br. J. Psychiatry 168, 57–60 (1996).
41. Monteleone, P., Tortorella, A., Borriello, R., Cassandro, P. & Maj, M. Prolactin hyperresponsiveness to D-fenfluramine in drug-free schizophrenia patients: a placebo controlled study. Biol. Psychiatry 45, 1606–1611 (1999).
42. Moreno, J. L. et al. Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia. Sci. Signal. 9, ra5 (2016).
43. Brea, J. et al. Evidence for distinct antagonist-revealed functional states of 5-hydroxytryptamine2A receptor homodimers. Mol. Pharmacol. 75, 1380–1391 (2009).
44. Gross-Isseroff, R., Salama, D., Israeli, M. & Biegon, A. Autoradiographic analysis of age-dependent changes in serotonin 5-HT2 receptors of the human brain postmortem. Brain Res. 519, 223–227 (1990).
45. Karrer, T. M., McLaughlin, C. L. & Guaglione, C. P. Reduced serotonin receptors and transporters in normal aging adults: a meta-analysis of PET and SPECT imaging studies. Neurobiol. Aging 80, 1–10 (2019).
46. Rivail, N. R. et al. Single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain. Int. J. Mol. Sci. 22, 835 (2021).
47. Underwood, M. D. et al. Serotonin receptors and suicide, major depression, alcohol use disorder and reported early life adversity. Transl. Psychiatry 8, 279 (2018).
48. Muguruza, C. et al. Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: effect of antidepressant treatment. Neuropsychopharmacology 36, 311–318 (2014).
49. Zhao, J. et al. Different stress-related gene expression in depression and suicide. J. Psychiatr. Res. 68, 176–185 (2015).